Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
New SteriPort manufacturing line
Civil construction, equipment, plant and machinery to set up a new SteriPort manufacturing line at the company's Hariyala site in Kheda, Gujarat.
New small volume parenteral line
Civil construction, equipment, plant and machinery to set up a new small volume parenteral manufacturing line at the same Hariyala site.
General corporate purposes
Ordinary corporate requirements, applied at the board's discretion.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Amanta Healthcare Limited is a Gujarat based pharmaceutical maker that specialises in sterile liquid products. Set up in December 1994, it develops, manufactures and markets parenteral formulations packed in plastic containers, using aseptic blow-fill-seal and injection stretch blow moulding processes in which the container is formed, filled and sealed in one continuous sterile operation. Its range covers fluid therapy such as intravenous fluids and diluents, ophthalmic solutions, respiratory care products and irrigation solutions, and it also makes medical devices including first-aid items and eye lubricants. Manufacturing is concentrated at a single site at Hariyala in Kheda district, Gujarat, spread over roughly 66,000 square metres and running several large-volume and small-volume parenteral lines. The plant is WHO-GMP compliant and holds ISO certifications covering quality, medical devices, environment and occupational safety. The company employed about 1,718 people as of March 2025 across manufacturing, formulation development and quality laboratories. It sells through three channels: a domestic branded business, an export business, and product partnering arrangements with other Indian and overseas pharmaceutical companies. More than 45 generic products are sold in India under its own brands through a network of around 320 stockists and distributors, and its products are registered in 19 countries, with branded shipments reaching 21 countries during the year to March 2025 across Africa, Latin America and the United Kingdom. Revenue has held in a narrow band near 275 crore rupees while profitability has improved sharply, from a loss in the year to March 2023 to a profit of about 10.5 crore rupees in the year to March 2025.
Ahead of the issue the company placed 30,00,000 shares with six anchor investors at 126 rupees per share, the top of the band, raising 37.80 crore rupees on 29 August 2025. That allocation was 60 percent of the institutional portion. The largest participants were Bandhan Small Cap Fund, which took 7,93,730 shares for about 10 crore rupees, and Sanshi Fund-1, which took 5,95,010 shares for about 7.5 crore rupees. Aarth Growth Fund, the Perpetuity Health to Wealth Rising Fund, the Sunrise Investment Opportunities Fund and the Finavenue Growth Fund made up the rest of the book.
Source: RHP • Analysis provided for informational purposes
Last Updated: 13 July 2026, 6:25 PM
Three decades in sterile liquids
The company has made sterile liquid formulations since 1994 and carries a broad catalogue across fluid therapy, ophthalmics, respiratory care and irrigation. That spread means no single therapy area determines the year.
Fill technology across volume ranges
Its blow-fill-seal and stretch blow moulding lines form, fill and seal the container in one sterile pass, and it runs both large and small volume lines. Few Indian makers cover that range of fill sizes in-house.
Regulator-cleared plant
The Hariyala facility is WHO-GMP compliant and holds ISO certifications for quality, medical devices, environment and workplace safety. Those approvals are what let it register products abroad.
Domestic reach plus exports
It sells its own brands through roughly 320 stockists and distributors in India while shipping to more than twenty countries and partnering on products for other drug companies. The three channels balance one another.
Revenue leans on few customers
A large share of sales comes from a small group of customers. Losing any one of them would show up immediately in the top line.
The expansion may slip
Most of the money raised goes into two new production lines, SteriPort and small volume parenterals. If those lines are late or run below plan, the growth case for the issue weakens.
Product liability is real here
Sterile injectables and intravenous fluids go straight into the bloodstream. A contamination or quality failure carries consequences well beyond a recall.
Amanta Healthcare Limited
8th Floor, Shaligram Corporates, C. J. Marg, Ambli, Ahmedabad, Gujarat 380058, India
View on Maps →MUFG Intime India Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Debt heavy relative to equity
Borrowings run about twice net worth, and part of that debt is unsecured and backed by personal guarantees from the promoters. There is little balance-sheet cushion if trading turns.
One plant, one site
All manufacturing sits at the single Hariyala facility in Gujarat. A regulatory action, fire or disruption there would halt essentially all production.